Compass’s psilocybin therapy advances toward FDA nod in severe depression
TL;DR Summary
Compass Pathways reports positive Phase 3 results for its psilocybin-based treatment COMP360 in two trials for severe depression, suggesting potential FDA approval, though full data are needed to confirm the magnitude of benefit; if approved, it could become the first psilocybin product on the market, following Spravato (ketamine derivative).
- Compass says its psilocybin drug helped patients with severe depression in two trials statnews.com
- Psilocybin data could be good enough for approval statnews.com
- Compass’ Psychedelic Shows Durability ‘In-Spades’ as Path to FDA Clears BioSpace
- Why Did Compass Pathways Stock Rocket Higher Today? Yahoo Finance
- Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push Fierce Biotech
Reading Insights
Total Reads
1
Unique Readers
3
Time Saved
2 min
vs 3 min read
Condensed
89%
444 → 49 words
Want the full story? Read the original article
Read on statnews.com